Abstract 5054
Background
Neoadjuvant Chemotherapy (NACT) followed by Interval Debulking Surgery (IDS) is an alternative frontline treatment in patients with advanced Epithelial Ovarian Cancer (EOC). Histopathologic assessment of tumor post NACT is an ideal mean of response to treatment. The present study aims to characterize the pathological response and to examine its prognostic significance in these patients.
Methods
Medical records of women with EOC treated at Alexandra Hospital from 2011 to 2016 were retrospectively identified. Clinicopathological data, treatment and survival data were analyzed. IDS specimens were reviewed by study pathologist and Chemotherapy Response Score (CRS), lymphocytic infiltration, necrosis and mitosis were assessed. Survival differences were estimated using the long-rank test.
Results
55 patients with EOC treated with NACT were identified, 48 had complete clinical and pathological data. Median age was 63 years. All patients had high grade disease and 45 of them had serous carcinoma. At baseline 38 patients had stage IIIc disease and 10 stage IV. All patients received Paclitaxel-Carboplatin combination for 3 cycles. 20 patients had complete debulking (no macroscopic residual disease), 18 had optimal (macroscopic disease <1cm) and 7 suboptimal. 22 patients received also bevacizumab as part of their treatment post IDS. CRS assessed at omentum predicted PFS when adjusted for age, stage, debulking status (complete, optimal, suboptimal) and post IDS bevacizumab administration (mPFS CRS 1vs2vs3: 11.9-14-19.5 months 95% CI [7.4-18.3], [12.2-20.7], [13.5-31.3]). Lymphocytic invasion was associated with improved OS (log-rank test p = 0.022). Presence of necrosis and mitosis per HPF did not predict either PFS or OS. BRCA status was known for 19 patients and presence of BRCA1/2 mutations was strongly correlated with lymphocytic infiltration (P = 0.011) but not CRS (p = 0.801).
Conclusions
Our study confirms the predictive value of CRS in EOC patients treated with NACT and IDS, but also demonstrates the prognostic significance of lymphocytic infiltration in IDS specimens. The later was associated with presence of BRCA mutations with obvious therapeutic implications.
Clinical trial identification
Legal entity responsible for the study
Michalis Liontos.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5964 - Longitudinal Assessment of Multiplex Patient-Specific ctDNA Biomarkers in Bladder Cancer for Diagnosis, Surveillance, and Recurrence
Presenter: Karin Birkenkamp-Demtröder
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2197 - Distinct functional consequences of HER2 gene amplification in colorectal and lung adenocarcinomas
Presenter: Evgeny Imyanitov
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2422 - Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: independent actors or reciprocal drivers? A translational study by Meet-Uro group
Presenter: Marzia Del Re
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2750 - Validation of a 90-gene assay for tissue origin diagnosis of brain metastases
Presenter: Yulong Zheng
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2960 - Development of a Pan-Cancer Biomarker Panel for Improved Detection of MSI Across all Cancer Types
Presenter: Jeff Bacher
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3791 - bMSI better predicts the responses to immune checkpoint inhibitors (ICI) than MMR/MSI from historical tissue specimens in metastatic gastrointestinal cancer patients
Presenter: Zhenghang Wang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5189 - Vall d’Hebron Institute of Oncology (VHIO) Immuno-Oncology prognostic index (VIO): a new tool for improved patient (pt) selection in Phase 1 (Ph1) trials with Immune Checkpoint Inhibitors (ICI).
Presenter: Cinta Hierro
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5372 - Augmenting TNM Staging with Machine Learning-based Immune Profiling for Improved Prognosis Prediction in Muscle-Invasive Bladder Cancer Patients
Presenter: Nicolas Brieu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2249 - HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma
Presenter: Alice Bernard-Tessier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2287 - Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis
Presenter: Marco Iafolla
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract